Performance Characteristics of the Abbott BinaxNOW SARS-CoV-2 Antigen Test in Comparison to Real-Time Reverse Transcriptase PCR and Viral Culture in Community Testing Sites during November 2020
- PMID: 34705535
- PMCID: PMC8769733
- DOI: 10.1128/JCM.01742-21
Performance Characteristics of the Abbott BinaxNOW SARS-CoV-2 Antigen Test in Comparison to Real-Time Reverse Transcriptase PCR and Viral Culture in Community Testing Sites during November 2020
Abstract
Point-of-care antigen tests are an important tool for SARS-CoV-2 detection. Antigen tests are less sensitive than real-time reverse transcriptase PCR (rRT-PCR). Data on the performance of the BinaxNOW antigen test compared to rRT-PCR and viral culture by symptom and known exposure status, timing during disease, or exposure period and demographic variables are limited. During 3 to 17 November 2020, we collected paired upper respiratory swab specimens to test for SARS-CoV-2 by rRT-PCR and Abbott BinaxNOW antigen test at two community testing sites in Pima County, Arizona. We administered a questionnaire to capture symptoms, known exposure status, and previous SARS-CoV-2 test results. Specimens positive by either test were analyzed by viral culture. Previously we showed overall BinaxNOW sensitivity was 52.5%. Here, we showed BinaxNOW sensitivity increased to 65.7% among currently symptomatic individuals reporting a known exposure. BinaxNOW sensitivity was lower among participants with a known exposure and previously symptomatic (32.4%) or never symptomatic (47.1%) within 14 days of testing. Sensitivity was 71.1% in participants within a week of symptom onset. In participants with a known exposure, sensitivity was highest 8 to 10 days postexposure (75%). The positive predictive value for recovery of virus in cell culture was 56.7% for BinaxNOW-positive and 35.4% for rRT-PCR-positive specimens. Result reporting time was 2.5 h for BinaxNOW and 26 h for rRT-PCR. Point-of-care antigen tests have a shorter turnaround time than laboratory-based nucleic acid amplification tests, which allows for more rapid identification of infected individuals. Antigen test sensitivity limitations are important to consider when developing a testing program.
Keywords: Abbott BinaxNOW SARS-CoV-2 Ag Card; COVID-19; SARS-CoV-2; antigen test; viral culture.
Figures
References
-
- U.S. Food and Drug Administration. 2021. In vitro diagnostics EUAs–antigen diagnostic tests for SARS-CoV-2. FDA, Silver Spring, MD. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-em....
-
- Abbott Diagnostics. 2020. BinaxNOW COVID-19 Ag card (PN 195–000)—instructions for use. https://www.fda.gov/media/141570/download.
-
- CMS. 2020. Updated CLIA SARS-CoV-2 molecular and antigen point of care test enforcement discretion. https://www.cms.gov/files/document/clia-sars-cov-2-point-care-test-enfor....
-
- U.S. Food and Drug Administration. 2020. COVID-19 test uses: FAQs on testing for SARS-CoV-2. FDA, Silver Spring, MD. https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-dev....
-
- U.S. Department of Health and Human Services. 2020. Coronavirus (COVID-19) testing: expanding access to coronavirus (COVID-19) testing. https://www.hhs.gov/coronavirus/testing/index.html.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
